Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Monday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other analysts have also recently commented on the stock. HC Wainwright upped their price target on shares of Aptose Biosciences from $2.00 to $6.00 and gave the company a “buy” rating in a research report on Friday, March 28th. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th.

Aptose Biosciences Price Performance

The firm has a market capitalization of $3.66 million, a P/E ratio of -0.58 and a beta of 1.04. The firm has a fifty day moving average of $4.41 and a two-hundred day moving average of $7.37. Aptose Biosciences has a 1-year low of $1.35 and a 1-year high of $50.10.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the quarter. Sigma Planning Corp owned about 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent reporting period. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.